This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Adults subjects (18-74)
Cutaneous sarcoidosis with characteristic skin biopsy histology
A CSAMI activity score ≥ 10
Weight > 40 kg to < 130 kg with BMI < 40 kg/m2 .
History of
Lymphoproliferative disorder
Active malignancy;
History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
Priovant Therapeutics, Inc.
Lead sponsor